-
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight
13 Jan 2026 18:00 GMT
… 529K
FDA-Approved Systemic Lupus Erythematosus Drugs: BENLYSTA ( … Therapies in Clinical Trials: Nipocalimab, Litifilimab, … treatment landscape includes just two FDA-approved therapies: BENLYSTA … , Qilu Pharmaceutical, ImmuPharma, Beijing Mabworks Biotech Co., …
-
J&J’s Imaavy posts win in Phase II SLE trial
07 Jan 2026 18:24 GMT
… trial, J&J will advance the therapy to Phase III trials … , the drug has gained approval for the treatment of adults … leaders previously interviewed by Pharmaceutical Technology, revamping formulations can … have to compete with Benlysta, which has seen strong …
-
[New Year's Analysis] Korea’s next homegrown drug could be a first local CAR-T as payer keeps widening access
06 Jan 2026 08:58 GMT
… and it cleared Mirum Pharmaceutical’s Livmarli (maralixibat) for … the drugs with expanded reimbursed use were Darzalex (daratumumab), Benlysta ( … GC Biopharma’s anthrax vaccine BARYTHRAX, Medytox’s fat … control.
Time-to-treatment is another point Curocell …
-
July - September 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
02 Jan 2026 17:02 GMT
… Reactions
Benlysta (belimumab) injection
Severe cutaneous adverse reactions
FDA is evaluating … and Acute Liver Failure Following Treatment with Elevidys and Revised … tablets
Orgovyx (relugolix) tablets
Drug interaction
FDA is evaluating the need for …
-
Approval of Roche/Genentech’s Gazyvaro Set to Reshape the EU5 Lupus Nephritis Treatment Landscape, According to Spherix Global Insights
11 Dec 2025 14:51 GMT
… biologic anchor in LN treatment. Clinicians report reassessing … share from GSK’s Benlysta. Nearly 30% of Class … into patient journeys and treatment outcomes. About RealTime Dynamix … highlights clinical decision-making, treatment sequencing, and outcomes for …
-
FDA Approval for Roche Cancer Drug Brings a New Biologic Option to Lupus Nephritis
20 Oct 2025 22:26 GMT
… immunosuppressants and anti-inflammatory drugs. Results showed that nearly … in cancer clinical trials included infusion-related reactions … cell survival. Benlysta’s 2011 FDA approval in systemic … week, a European Medicines Agency committee recommended approval …
-
Roche's aging oncology blockbuster Gazyva snares FDA nod to move into lupus nephritis
21 Oct 2025 00:23 GMT
… long-approved blood cancer medicine Gazyva.
Early Monday, … it stands, the lupus treatment market—across several distinct … by GSK’s biologic Benlysta. The drug, which falls into … FDA nod for its drug Saphnelo to treat moderate to severe SLE.
Doctors …
-
As Roche/Genentech’s Obinutuzumab (Gazyva) Nears FDA Decision, Spherix Global Insights White Paper Reveals Keys to Successful Lupus Product Launches
02 Oct 2025 13:11 GMT
… , MD, Professor of Medicine at Johns Hopkins University … analysis of 15 drug launches between 2020 … treatment landscape continues to expand rapidly. The approvals for Benlysta … FDA and EMA decisions in 2025 following positive Phase III REGENCY trial …
-
Indian pharma cos to benefit as drugs worth $236 billion expected to go off-patent in next five years
30 Sep 2025 04:39 GMT
… biosimilars. With 750+ US FDA-approved plants, India is … steep as they get. Medicines worth $236 billion are … Genentech) - HER2+ Breast Cancer, Benlysta (GSK) – Lupus, Elelyso (Pfizer … of generic drugs and especially benefit Indian pharmaceutical companies that …
-
Global Benlysta Market Forecast To Reach $3.6 Billion By 2029 With 11.2% Annual Growth
28 Jul 2025 12:53 GMT
… in immunology, innovative drug delivery systems, collaborations … on medical goods and services, including hospital care, pharmaceuticals, … increased investment in treatments for chronic autoimmune … 47;report/benlysta-global-market-report
What …
About
© 1995-2026